S
Suzhou Minor Pharmaceutical Technology
Small molecule drug integrated research and development services
About Suzhou Minor Pharmaceutical Technology
Suzhou Minor Pharmaceutical Technology Co., Ltd. (Medinoah) is a contract development and manufacturing organization (CDMO) focused on small molecule chemical drugs. Founded in December 2008 by Dr. Yanong Daniel Wang, the company is headquartered in the BioBay of Suzhou Industrial Park, China. Dr. Wang holds a Ph.D. in Organic Chemistry from the University of Delaware and previously served as a principal scientist at Wyeth in the United States, where he gained extensive experience in new drug development and R&D management.
Medinoah provides an integrated, end-to-end service chain for both innovative and generic drugs, catering to the needs of domestic and international pharmaceutical enterprises at various stages of drug research. The company's core business encompasses Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), and Chemistry, Manufacturing, and Controls (CMC) services. Its offerings include preclinical chemical research, custom synthesis of high-end products, process chemistry, and the production of Active Pharmaceutical Ingredients (APIs) and intermediates. The firm also specializes in complex chemistries such as chiral compounds and antibody-drug conjugates (ADCs).
The company operates a business model that provides full-chain services from early-stage research and process optimization to pilot-scale and GMP-compliant production for commercialization. Medinoah has established a research and development center in Hefei and a GMP-certified manufacturing plant in Zouping, Shandong, enabling it to offer one-stop-shop services to its clients. The company has received multiple rounds of funding, with its most recent B-round financing completed in February 2024.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2023 | $14M | $55M | Addor Capital · Oriza Holdings · National Small and Medium Enterprise Development | ↗ |
Growth signals
Latest recorded traffic for Suzhou Minor Pharmaceutical Technology is 150 monthly website visits, up 0% over the last three months. Suzhou Minor Pharmaceutical Technology's team grew 0% over the past year.
Open positions
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Minor Pharmaceutical Technology in the Suzhou Shi ecosystem
The Suzhou Minor Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Addor Capital
Oriza Holdings
National Small and Medium Enterprise Development
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Minor Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Minor Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.